KKR nears deal to buy medical device maker Integer for more than $4bn

Affected assets and topics

Expected market reaction

Evidence trail

Prediction lifecycle

• Rule-Based Analysis not AI KKR Neutral 50% 6h
  Generated → 6h → Excluded

  Excluded: no stored price within tolerance of this prediction's maturity, checked by rescore_expired_predictions

Logged at publication, scored automatically once the window closes — never edited.

Original source

Healthcare company was recently targeted by an activist hedge fund established by an Elliott Management alumnus

Read the full article on Financial Times

Original article published by Financial Times on July 31, 2026. Analysis and insights provided by AnalystMarkets AI.

More of the KKR narrative

• 06:00 CVC Raises $10 Billion for Its Largest-Ever Secondaries Fund Bloomberg
• 18:37 SEC Preps Plan to Widen Investor Access to Private Markets Bloomberg
• 07:46 Private Markets Set for Delay in Tapping German Pension Cash Bloomberg
• 17:38 KKR is the rare private equity firm that bets on itself Financial Times